1 unchanged sentence
Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangements
−Removed: During the three months ended June 30, 2024, neither the Company or any of its officers or directors adopted or terminated trading arrangements for the sale of the Company’s common stock .
−Removed: 3.1 Articles of Incorporation of Registrant, as amended (incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K filed on March 22, 2024)
−Removed: 3.2 Amended and Restated Bylaws of Registrant (incorporated by reference to Exhibit 3.2 to our Annual Report on Form 10-K filed on March 2, 2021)
−Removed: 2024 Inducement Equity Incentive Plan
−Removed: Form of Stock Option Grant Notice and Stock Option Agreement under the 2024 Inducement Equity Incentive Plan
−Removed: Form of Restricted Stock Unit Award Grant Notice and Restricted St ock Unit Award Agreement under the 2024 Inducement Equity Incentive Plan
−Removed: Equity Distribution Agreement, dated as of May 10, 2024, by and between Skye Bioscience, Inc.
−Removed: and Piper Sandler & Co.
−Removed: (incorporated by reference to Exhibit 1.2 to our Registration Statement on Form S-3 filed May 10, 2024)
+Added: During the three months ended September 30, 2024, neither the Company or any of its officers (as that term is defined by the SEC in Rule 16a-1(f) under the Exchange Act) or directors adopted or terminated a Rule 10b5-1 trading arrangement or a non Rule 10b5-1 trading arrangement for the sale of the Company’s common stock .
+Added: 3.1 Amended and Restated Articles of Incorporation of Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 22, 2024)
+Added: 3.2 Amended and Restated Bylaws of Registrant (incorporated by reference to Exhibit 3.2 to our Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 2, 2021)
+Added: Skye Bioscience, Inc.
+Added: Amended and Restated Omnibus Incentive Plan
+Added: E mployment Agreement between the R egistrant and Dr.
+Added: Puneet Arora (incorporated by ref ere nce to Exhib it 10.1 to the Re gistrant's Current Report on Form 8-K filed with the SEC on September 4, 2024)
31.1* Certification of Principal Executive Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934
5 unchanged sentences
101 The following materials from the Skye Biosciences, Inc.
−Removed: Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline Extensible Business Reporting Language (iXBRL):
+Added: Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, formatted in Inline Extensible Business Reporting Language (iXBRL):
(i) Condensed Consolidated Balance Sheets (Unaudited), (ii) Condensed Consolidated Statements of Operations (Unaudited), (iii) Condensed Consolidated Statements of Cash Flows (Unaudited), (iv) Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited), and (v) related Notes to the Unaudited Condensed Consolidated Financial Statements.
6 unchanged sentences
a Nevada corporation
−Removed: August 9, 2024 By:
+Added: November 7, 2024 By:
/s/ Punit Dhillon
Punit Dhillon
−Removed: Chief Executive Officer, Secretary, Chairman of the Board, and Director
+Added: Chief Executive Officer, Secretary and Director
(Principal Executive Officer)
−Removed: August 9, 2024 By:
+Added: November 7, 2024 By:
/s/ Kaitlyn Arsenault
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.